Terms: = Gastric cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Clinical Outcome
24 results:
1. clinical features and outcomes of advanced her2+ esophageal/GEJ cancer with brain metastasis.
Liang K; Feliciano JL; Marrone KA; Murray JC; Hann CL; Anagnostou V; Tackett SA; Shin EJ; Hales RK; Voong KR; Battafarano RJ; Yang SC; Broderick SR; Ha JS; Forde PM; Brahmer JR; Lam VK
ESMO Open; 2024 Jan; 9(1):102199. PubMed ID: 38071928
[TBL] [Abstract] [Full Text] [Related]
2. Gasdermin B over-expression modulates her2-targeted therapy resistance by inducing protective autophagy through Rab7 activation.
Gámez-Chiachio M; Molina-Crespo Á; Ramos-Nebot C; Martinez-Val J; Martinez L; Gassner K; Llobet FJ; Soriano M; Hernandez A; Cordani M; Bernadó-Morales C; Diaz E; Rojo-Sebastian A; Triviño JC; Sanchez L; Rodríguez-Barrueco R; Arribas J; Llobet-Navás D; Sarrió D; Moreno-Bueno G
J Exp Clin Cancer Res; 2022 Sep; 41(1):285. PubMed ID: 36163066
[TBL] [Abstract] [Full Text] [Related]
3. Targeting the histone demethylase PHF8-mediated PKCα-Src-PTEN axis in her2-negative gastric cancer.
Tseng LL; Cheng HH; Yeh TS; Huang SC; Syu YY; Chuu CP; Yuh CH; Kung HJ; Wang WC
Proc Natl Acad Sci U S A; 2020 Oct; 117(40):24859-24866. PubMed ID: 32958674
[TBL] [Abstract] [Full Text] [Related]
4. Complete Remission of Metastatic her2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment.
Gutting T; Schulte N; Belle S; Betge J; Härtel N; Wilke J; Weers J; Ebert MP; Zhan T
J Gastrointestin Liver Dis; 2019 Dec; 28(4):503-507. PubMed ID: 31826054
[TBL] [Abstract] [Full Text] [Related]
5. O-glycans truncation modulates gastric cancer cell signaling and transcription leading to a more aggressive phenotype.
Freitas D; Campos D; Gomes J; Pinto F; Macedo JA; Matos R; Mereiter S; Pinto MT; Polónia A; Gartner F; Magalhães A; Reis CA
EBioMedicine; 2019 Feb; 40():349-362. PubMed ID: 30662000
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathologic study of 10 cases of gastric adenocarcinoma with hepatoid or enteroblastic differentiation.
Kuroda N; Yorita K
Pol J Pathol; 2018; 69(2):128-135. PubMed ID: 30351859
[TBL] [Abstract] [Full Text] [Related]
7. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract] [Full Text] [Related]
8. Tribody [(her2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract] [Full Text] [Related]
9. Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study.
Birkness JE; Spada NG; Miller C; Luketich JD; Nason KS; Sun W; Davison JM
Genes Chromosomes Cancer; 2018 Jan; 57(1):28-34. PubMed ID: 28913947
[TBL] [Abstract] [Full Text] [Related]
10. Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer.
Clermont PL; Fornaro L; Crea F
Epigenomics; 2017 Oct; 9(10):1329-1335. PubMed ID: 28875726
[TBL] [Abstract] [Full Text] [Related]
11. Depth of response predicts the clinical outcome of advanced her2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
[TBL] [Abstract] [Full Text] [Related]
12. clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review.
Ghidini M; Petrelli F; Hahne JC; De Giorgi A; Toppo L; Pizzo C; Ratti M; Barni S; Passalacqua R; Tomasello G
Med Oncol; 2017 Apr; 34(4):62. PubMed ID: 28315230
[TBL] [Abstract] [Full Text] [Related]
13. Quantitative proteomic analysis of her2 expression in the selection of gastric cancer patients for trastuzumab treatment.
An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
[TBL] [Abstract] [Full Text] [Related]
14. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
[TBL] [Abstract] [Full Text] [Related]
15. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in her2-positive gastric cancer.
Lee JY; Hong M; Kim ST; Park SH; Kang WK; Kim KM; Lee J
Sci Rep; 2015 Mar; 5():9289. PubMed ID: 25786580
[TBL] [Abstract] [Full Text] [Related]
16. Predictive value of serum her2 ECD in patients with her2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
[TBL] [Abstract] [Full Text] [Related]
17. A novel gene-protein assay for evaluating her2 status in gastric cancer: simultaneous analyses of her2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
[TBL] [Abstract] [Full Text] [Related]
18. MET activation mediates resistance to lapatinib inhibition of her2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract] [Full Text] [Related]
19. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Wainberg ZA; Lin LS; DiCarlo B; Dao KM; Patel R; Park DJ; Wang HJ; Elashoff R; Ryba N; Hecht JR
Br J Cancer; 2011 Sep; 105(6):760-5. PubMed ID: 21811258
[TBL] [Abstract] [Full Text] [Related]
20. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.
Iqbal S; Goldman B; Fenoglio-Preiser CM; Lenz HJ; Zhang W; Danenberg KD; Shibata SI; Blanke CD
Ann Oncol; 2011 Dec; 22(12):2610-2615. PubMed ID: 21415234
[TBL] [Abstract] [Full Text] [Related]
[Next]
